NCT02965716 2025-11-18
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04068181 2025-01-07
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Phase 2 Completed
NCT03842943 2024-05-02
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
University of Louisville
Phase 2 Recruiting
NCT04427306 2023-09-15
Neoadjuvant T-VEC in High Risk Early Melanoma
University of California, Davis
Phase 2 Suspended
NCT02890368 2023-04-05
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
Phase 1 Terminated
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT02366195 2021-11-30
TVEC-325
Amgen
Phase 2 Completed
NCT03555032 2021-08-18
TITAN
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT03747744 2020-12-29
myDCTV
Universitair Ziekenhuis Brussel
Phase 1 Unknown
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT02014441 2019-11-20
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Amgen
Phase 2 Completed
NCT00289016 2015-12-18
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
BioVex Limited
Phase 2 Completed
NCT02574260 2015-12-17
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
BioVex Limited
Phase 2 Completed